55
Days Left
Lead Plaintiff Deadline
Dec 7, 2026
Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
The filed complaint alleges that The Chemours Company made materially false and/or misleading statements and/or failed to disclose that: (i) defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of defendants’ overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, defendants’ financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.
Investors who purchased or otherwise acquired The Chemours Company securities within the class period described above and suffered losses may be eligible.
If you suffered a loss in The Chemours Company during the relevant time frame or pursuant to the relevant offering(s), you have until December 7, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
● The Allegation: The complaint alleges Chemours overstated aftermarket demand for its Opteon refrigerant products and concealed that demand was falling because the company had oversold those products in the prior fiscal year, allegedly rendering its 2026 financial guidance unreliable even as management publicly touted a "really, really strong position in the aftermarket."
● The Stock Drop: On August 5, 2026, CC fell $3.34 per share, or 18.63%, to close at $14.59 per share after Chemours cut its full-year adjusted EBITDA guidance and management admitted an oversupplied aftermarket channel heading into 2026.
● Class Period & Defendants: The class period runs from February 20, 2026 through August 4, 2026, inclusive. The named defendants are The Chemours Company, Denise Dignam (President and Chief Executive Officer), and Shane Hostetter (Senior Vice President and Chief Financial Officer).
● Lead Plaintiff Deadline: December 7, 2026. Investors who wish to seek appointment as lead plaintiff must apply by the deadline.
|
Chemours Class Action Summary |
|
|
Company |
The Chemours Company (NYSE: CC) |
|
Lead Plaintiff Deadline |
December 7, 2026 |
|
Class Period |
February 20, 2026 – August 4, 2026 |
|
Stock Drop |
August 5, 2026 – CC fell $3.34 (18.63%) to $14.59 |
A securities class action lawsuit has been filed against The Chemours Company (NYSE: CC). The plaintiff brings the case on behalf of investors who bought Chemours securities. The class period runs from February 20, 2026 through August 4, 2026.
The complaint alleges the company made materially false and misleading statements about demand for its Opteon refrigerant products. It claims Chemours hid that it had oversold these products the year before. As a result, the lawsuit says, the company's 2026 financial guidance could not be trusted.
On August 4, 2026, Chemours cut its full-year adjusted EBITDA guidance. During an earnings call the next morning, management disclosed an oversupplied aftermarket channel. The stock fell that day by $3.34 per share, or 18.63%, to close at $14.59. The complaint alleges investors suffered significant losses as a result.
The Chemours Company offers a range of industrial and specialty chemical products for markets including refrigeration and air conditioning. The company reports results from products such as Opteon, a set of refrigeration chemicals with a near-zero ozone-depletion footprint, within its Thermal & Specialized Solutions (TSS) segment. Chemours is headquartered in Wilmington, Delaware, and its common stock trades on the New York Stock Exchange under the ticker symbol CC.
February 20, 2026–August 4, 2026
Investors who purchased or acquired The Chemours Company (CC) securities during the Class Period may be eligible to seek recovery under the federal securities laws.
The complaint centers on Chemours's Thermal & Specialized Solutions segment and its Opteon refrigerant products, whose growth the company told investors was supported in part by the adoption of the American Innovation and Manufacturing Act (U.S. AIM Act). That 2020 law directed the U.S. Environmental Protection Agency to oversee a transition to refrigerants with a lesser impact on the ozone layer. According to the complaint, defendants repeatedly tied the company's performance and guidance to regulatory-driven demand under the U.S. AIM Act.
The class period begins on February 20, 2026, the day after Chemours reported record fourth-quarter Opteon growth of 37% and projected full-year 2026 adjusted EBITDA of $800 million to $900 million. On the accompanying earnings call, Defendant Dignam touted a "fourth quarter record for Opteon sales," and Defendant Hostetter forecast continued double-digit Opteon growth and reaffirmed the company's full-year guidance. When pressed by an analyst, Dignam stated defendants had "full confidence in our full year guide."
The lawsuit claims these representations continued into the first quarter of 2026. On May 5, 2026, Chemours reported record first-quarter TSS results and again reaffirmed its full-year adjusted EBITDA range. On the following earnings call, Dignam described the company's "really, really strong position in the aftermarket" and expressed optimism about growth for the rest of the year, while Hostetter reaffirmed the previously announced annual guidance.
The complaint alleges these statements were materially false and misleading because defendants had materially overstated aftermarket demand for Opteon products, demand was decreasing as a result of the company overselling Opteon products in the preceding fiscal year, and, as a result, defendants' 2026 financial guidance was unreliable. The filing further alleges the Individual Defendants knew or recklessly disregarded these facts given their positions and access to non-public information, and that they sold a combined 26,671 shares of Chemours common stock for over $485,000 in proceeds during the class period.
After market hours on August 4, 2026, Chemours announced second-quarter 2026 financial results and reduced its full-year adjusted EBITDA guidance to $775 million to $825 million, down from $800 million to $900 million. The company reported net sales of $1.6 billion, a year-over-year decrease of approximately 1%, which it attributed to a 4% decline in volumes. Chemours connected the volume decline to lower TSS Opteon blends aftermarket refrigerant sales compared with elevated demand a year earlier tied to the initial aftermarket channel fill under the U.S. AIM Act.
During the accompanying earnings call on the morning of August 5, 2026, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Defendant Hostetter quantified the impact, stating that approximately $65 million in aftermarket sales had been pulled forward into 2025 from 2026. According to the complaint, these admissions departed sharply from Dignam's earlier representation that the company enjoyed a "really, really strong position in the aftermarket."
In the days that followed, several analysts lowered their price targets for Chemours stock. UBS downgraded the stock from Buy to Neutral and cut its target 37.9%, citing analysis indicating Chemours "did oversell products in 2025 and likely early 2026." Morgan Stanley and J.P. Morgan also reduced their targets, with J.P. Morgan noting the revenue contraction in the TSS segment "was a surprise to the market."
On August 5, 2026, following the disclosure of the reduced guidance and the admission of an oversupplied aftermarket channel, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share. The complaint alleges that this precipitous decline in the market value of the company's securities caused significant losses and damages to the plaintiff and other class members who had purchased Chemours securities at prices allegedly inflated by the challenged statements.
● Lead Plaintiff Deadline: December 7, 2026
● After the lead plaintiff deadline, the Court will consider any lead plaintiff motions.
● Defendants may file a motion to dismiss.
● If the case proceeds, the Court may later consider class certification.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. Prior results do not guarantee similar outcomes.
The lawsuit alleges that The Chemours Company (NYSE: CC) made materially false and misleading statements about demand for its Opteon refrigerant products within its Thermal & Specialized Solutions segment. According to the complaint, defendants overstated aftermarket demand and failed to disclose that demand was decreasing because the company had oversold Opteon products in the prior fiscal year. The complaint alleges these undisclosed issues rendered Chemours's 2026 financial guidance unreliable. After Chemours reduced its full-year adjusted EBITDA guidance on August 4, 2026, and management disclosed an oversupplied channel on August 5, the stock fell sharply.
The class period runs from February 20, 2026 through August 4, 2026, inclusive. According to the complaint, this period begins the day after Chemours reported record fourth-quarter Opteon growth and issued full-year 2026 adjusted EBITDA guidance of $800 million to $900 million. It ends on August 4, 2026, when Chemours announced reduced full-year guidance and reported lower Opteon aftermarket refrigerant sales. Management discussed an oversupplied aftermarket channel the following morning. Investors who purchased or acquired Chemours securities during this period may be eligible to seek recovery under the federal securities laws.
The defendants are The Chemours Company and two of its senior executives. Denise Dignam has served as the company's President and Chief Executive Officer at all relevant times, and Shane Hostetter has served as Senior Vice President and Chief Financial Officer. The complaint refers to Dignam and Hostetter as the Individual Defendants and alleges they had the power and authority to control the contents of Chemours's SEC filings, press releases, and other market communications. The lawsuit also asserts control person claims against the Individual Defendants under Section 20(a) of the Exchange Act.
According to the complaint, on August 4, 2026, after market hours, Chemours announced second-quarter 2026 results and reduced its full-year adjusted EBITDA guidance to $775 million to $825 million. Management admitted on the accompanying earnings call on August 5, 2026, that the initial channel fill had led aftermarket customers to build additional inventory, creating an oversupplied channel heading into 2026. On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026. Several analysts then lowered their price targets for the stock.
Opteon is a set of refrigeration chemicals Chemours sells within its Thermal & Specialized Solutions segment. The complaint alleges Chemours repeatedly represented that it held a strong position in the aftermarket and that demand was being driven by the U.S. AIM Act transition. The lawsuit claims the company had actually oversold Opteon products in the prior fiscal year, leaving distributors with excess inventory. On August 5, 2026, management quantified roughly $65 million of aftermarket sales that it said should have been allocated to the current year, reflecting what the complaint describes as an oversupplied channel.
Investors who purchased or acquired Chemours (NYSE: CC) securities during the class period of February 20, 2026 through August 4, 2026 may be eligible to participate. Investors who wish to seek appointment as lead plaintiff must apply to the Court by the applicable deadline. The lead plaintiff is typically the investor or group of investors with the largest financial interest who is adequate and typical of the class. Class members who do not seek to become lead plaintiff may still be eligible to share in any potential recovery.
The lead plaintiff deadline is December 7, 2026.
The lawsuit alleges The Chemours Company (NYSE: CC) overstated aftermarket demand for its Opteon refrigerant products and concealed that it had oversold those products the prior year, allegedly making its 2026 financial guidance unreliable.
The class period runs from February 20, 2026 through August 4, 2026, inclusive. Investors who purchased Chemours securities during this period may be eligible to seek recovery under the federal securities laws.
On August 4, 2026, Chemours cut its full-year adjusted EBITDA guidance. The next morning, management disclosed an oversupplied aftermarket channel. CC fell $3.34 per share, or 18.63%, to close at $14.59 on August 5, 2026.
The defendants are The Chemours Company, President and Chief Executive Officer Denise Dignam, and Senior Vice President and Chief Financial Officer Shane Hostetter.
The lead plaintiff deadline is December 7, 2026.
Deadline
Dec 7, 2026